Open-label investigation shows increased expression of gene signatures in melanoma, indicating potential immune response.
Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expression of gene signatures representing immune cell density and upregulation of functional signatures.
No takes yet. Share an insight, caveat, or question.
Ribas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: